SAS Output

22-SEP-2017 18:10

LEUK ACCRUAL REPORT - Open and Recently Closed Studies

The REPORT Procedure

Detailed and/or summarized report

Table 1

SWOG/
Support
STUDY R
E
G
O
P
E
N
ARM ACCR.
GOAL
TOTAL
REGS.
REGS.
LAST
12
Month
REGS.
LAST
6
Month
REGS.
LAST
3
Month
REGS.
LAST
30
DAYS
REGS.
LAST
7
DAYS
DATE OF
FIRST
REG.
# of
ACT.
INSTs
# of
CURR
IRBs
SWOG S1203-AML, Age 18-60, 7+3/IA/IA+V 1 N 1 AraC + Daunorubicin 784 263 0 0 0 0 0 04/01/2013    
        2 AraC + Idarubicin   267 0 0 0 0 0      
        3 Vorinostat + AraC + Idarubicin   224 0 0 0 0 0      
            754 0 0 0 0 0      
 
    2 Y 4 AraC 784 165 0 0 0 0 0 04/01/2013    
        5 AraC + Idarubicin   161 0 0 0 0 0      
        6 Vorinostat + AraC + Idarubicin   135 0 0 0 0 0      
            461 0 0 0 0 0      
 
  S1312-ALL, CD22+, REL/REF, Inotuzumab+CVP 1 Y 1 CVP + Inotuzumab dose level 1 38 5 0 0 0 0 0 06/13/2014 4 5
        2 CVP + Inotuzumab dose level 2   5 0 0 0 0 0      
        3 CVP + Inotuzumab dose level 3   11 0 0 0 0 0      
        4 CVP + Inotuzumab dose level 4   5 0 0 0 0 0      
        5 CVP + Inotuzumab dose level 5   11 11 3 1 0 0      
            37 11 3 1 0 0      
 
  S1318-ALL, Age 65+, Ph±, Blinatumomab 1 Y 1 Induction: Ph- 44 31 21 14 4 3 0 06/30/2015 176 73
        2 Induction: Ph+/Ph-like   16 12 6 0 0 0      
            47 33 20 4 3 0      
 
    2 Y 3 Post-remission: Ph- 44 19 13 10 4 1 0 06/30/2015    
        4 Post-remission: Ph+/Ph-like   12 10 8 4 0 0      
            31 23 18 8 1 0      
 
    3 Y 5 Maintenance: Ph- 44 8 7 3 3 1 0 06/30/2015    
        6 Maintenance: Ph+/Ph-like   4 4 3 2 2 1      
            12 11 6 5 3 1      
 
  S0805-Ph+ ALL, Dasatinib/CVAD +/- BMT 1 N 1 Induction/Consolidation 94 97 0 0 0 0 0 08/25/2010 35 17
            97 0 0 0 0 0      
 
    2 Y 2 Vincristine/Pred/Dasatinib   22 0 0 0 0 0 08/25/2010    
            22 0 0 0 0 0      
 
    3 Y 3 Allo stem cell transplant 37 43 0 0 0 0 0 08/25/2010    
            43 0 0 0 0 0      
 
    4 Y 4 Dasatinib   42 0 0 0 0 0 08/25/2010    
            42 0 0 0 0 0      
 
  S0919-Rel AML: Pravastatin+Ida+Ara-C 1 N 0 Relapsed with previous remission > 3 months 110 36 0 0 0 0 0 12/10/2009 80 27
        1 Disease status: MDS transformed to AML;   29 7 0 0 0 0      
        2 Disease status: Refractory or relapsed with previous remission < 6 months;   50 0 0 0 0 0      
            115 7 0 0 0 0      
 
    2 N 0 Relapsed with previous remission > 3 months   10 0 0 0 0 0 12/10/2009    
        1 Disease status: MDS transformed to AML;   1 1 0 0 0 0      
        2 Disease status: Refractory or relapsed with previous remission < 6 months;   4 0 0 0 0 0      
            15 1 0 0 0 0      
 
Yes E1910-BCR-ABL-neg, B ALL, Blinatumomab 1 E Total Registrations   66 29 14 5 1 1 06/06/2014 167 92
            66 29 14 5 1 1      
 
  E2906-AML, Age 60+, Clo vs Dauno+Cy 1 E Total Registrations   75 0 0 0 0 0 08/06/2012 152 80
            75 0 0 0 0 0      
 
No E1910-BCR-ABL-neg, B ALL, Blinatumomab 0 E Total Registrations   90 42 20 9 1 0 06/06/2014 167 92
            90 42 20 9 1 0      
 
    2 E Total Registrations   43 15 11 5 1 0 06/06/2014    
            43 15 11 5 1 0      
 
    3 E Total Registrations   36 12 10 4 2 1 06/06/2014    
            36 12 10 4 2 1      
 
    4 E Total Registrations   14 1 0 0 0 0 06/06/2014    
            14 1 0 0 0 0      
 
  E2906-AML, Age 60+, Clo vs Dauno+Cy 0 E Total Registrations   19 0 0 0 0 0 08/06/2012 152 80
            19 0 0 0 0 0      
 
    2 E Total Registrations   21 0 0 0 0 0 08/06/2012    
            21 0 0 0 0 0      
 
    3 E Total Registrations   11 0 0 0 0 0 08/06/2012    
            11 0 0 0 0 0      
 
  NHLBIMDS-LEUK, National MDS Study 1 E Total Registrations   5 5 3 1 0 0 12/22/2016 62 27
            5 5 3 1 0 0      
 

22-SEP-2017 18:10

LEUK Recently Closed Studies Accrual Report

The REPORT Procedure

Detailed and/or summarized report

Table 1

OPEN Study Date
Closed
Reg. Arm Total
Regs
Regs
Last
30 Days
Regs
Last
7 Days
N S0919-Rel AML: Pravastatin+Ida+Ara-C 15-Sep-17 1 1 Pravastatin+Idarubicin+Ara-C 115 0 0
      2 2 Pravastatin+Idarubicin+Ara-C 15 0 0